On June 23, a delegation from Yuexiu Group visited the Shenzhen-Hong Kong Cell Valley for exchanges on cell and gene therapy, precision health management, and related industrial cooperation. The visiting delegation included Jiang Ying, Board Secretary and General Manager of the General Office of Yuexiu Group; Pan Yongqiang, General Manager of the Group's Capital Management Department and Chairman of Yuexiu Health; and Miao Tian, Deputy General Manager (presiding over overall work) of the Group's Science, Technology and Innovation Department and Executive Deputy General Manager (presiding over overall work) of Yuexiu Health.

Also participating in the visit were Jin Sisi, Deputy General Manager of Yuexiu Health, and Liu Yingjie and Li Yutian, Directors of the Business Development Department. Representing the Cell Valley Group were Chairman and General Manager Shi Yuanyuan, Chief Scientist Wang Jianxun, and Deputy General Manager and General Manager of Guangzhou Cell Valley Xiang Hua.

During the symposium, Chairman Shi Yuanyuan introduced the Cell Valley Group's progress in cell and gene therapy technology platforms, clinical research translation, industrialization services, and regional Cell Valley layout. The two sides engaged in in-depth exchanges on the application prospects of cell technology in healthcare, wellness services, industrial investment, and regional coordinated development.

Both parties expressed their intention to further leverage their respective strengths in capital, industry, healthcare resources, and cell technology platforms, actively explore entry points for cooperation, and jointly promote the high-quality development of the broader health industry.

About Yuexiu Group

Established in Hong Kong in 1985, Yuexiu Group is one of Guangzhou's largest municipal state-owned enterprises and a "Double Hundred Enterprise" under the State Council's state-owned enterprise reform program. The Group has formed a "3+3" industrial system, with finance, real estate, and transportation infrastructure as its core pillar industries, and food, broader health, and high-end smart manufacturing as its emerging cultivated sectors. It holds six listed platforms including Yuexiu Capital and Yuexiu Property, spanning primary, secondary, and tertiary industries and connecting domestic and international markets. In 2025, the Group's consolidated assets reached RMB 1,059.6 billion, with operating revenue of RMB 127.7 billion and total profit of RMB 6.5 billion. It ranked 209th among China's Top 500 Enterprises and 10th among China's Top 100 Transnational Corporations.